Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on 18F–Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL-Reference-Cited by-同舟云学术

Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on 18F–Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL

Published:2022-02-17 Issue:7 Volume:47 Page:664-665
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Lu Yang

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference8 articles.

1. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer;AJR Am J Roentgenol,1984

2. Leuprolide therapy for prostate cancer. An association with scintigraphic “flare” on bone scan;Clin Nucl Med,1990

3. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer;Eur J Nucl Med Mol Imaging,2011

4. Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer;Prostate Cancer Prostatic Dis,2019

5. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer;Eur Urol Oncol,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flare Phenomenon After 177Lu-DOTA-IBA Therapy in Bone Metastases of Lung Cancer;Clinical Nuclear Medicine;2024-06-18

2. Enchondroma on Bone Scan and PSMA PET/CT in a Patient With Prostate cancer;Clinical Nuclear Medicine;2024-03-25

3. Pluvicto-Induced 18F-PSMA PET Bone Flare;Clinical Nuclear Medicine;2024-02-22

4. Abiraterone;Reactions Weekly;2022-08-06

5. Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients With Prostate Cancer on 18F–Prostate-Specific Membrane Antigen PET/CT;Clinical Nuclear Medicine;2022-07-15